Do analysts rate PTPI or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 239.56%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PTPI or CNSP more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% CNS Pharmaceuticals N/A -204.25% -141.87%

Is PTPI or SRNE more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Sorrento Therapeutics N/A N/A N/A

Do analysts recommend CERO or PTPI?

CERo Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 249,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CERo Therapeutics is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CERO or PTPI more profitable?

CERo Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts prefer PRPH or PTPI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PTPI or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% NKGen Biotech N/A N/A -479.36%

Petros Pharmaceuticals (PTPI) Competitors

$0.0050 +0.00 (+6.38%)

As of 09/3/2026 02:37 PM Eastern

Compare

PTPI vs. CNSP, SRNE, CERO, PRPH, and NKGN

Should you buy Petros Pharmaceuticals stock or one of its competitors? Petros Pharmaceuticals's main competitors and comparable companies include CNS Pharmaceuticals (CNSP), Sorrento Therapeutics (SRNE), CERo Therapeutics (CERO), ProPhase Labs (PRPH), and NKGen Biotech (NKGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Neutral

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

Petros Pharmaceuticals has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market.

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 239.56%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Sorrento Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Petros Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Petros Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.17	N/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Sorrento Therapeutics	Neutral

Sorrento Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Sorrento Therapeutics	N/A	N/A	N/A

Summary

Petros Pharmaceuticals beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

CERo Therapeutics has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than CERo Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CERo Therapeutics had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for Petros Pharmaceuticals. CERo Therapeutics' average media sentiment score of 0.05 beat Petros Pharmaceuticals' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Petros Pharmaceuticals	Neutral

CERo Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 249,900.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CERo Therapeutics is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CERo Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats CERo Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Petros Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Petros Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Petros Pharmaceuticals' return on equity of -78.22% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

ProPhase Labs has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than ProPhase Labs. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.07	-$53.36M	-$2.25	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Petros Pharmaceuticals beats ProPhase Labs on 10 of the 12 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to NKGen Biotech?

Petros Pharmaceuticals (NASDAQ:PTPI) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
NKGen Biotech	Neutral

Petros Pharmaceuticals has higher revenue and earnings than NKGen Biotech. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

NKGen Biotech's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
NKGen Biotech	N/A	N/A	-479.36%

Petros Pharmaceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Petros Pharmaceuticals beats NKGen Biotech on 6 of the 9 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$156K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	0.03	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.33	12.92	6.14
Net Income	-$8.16M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.01 +6.4%	N/A	-82.1%	$156K	$5.11M	N/A	20	Gap Down
CNSP CNS Pharmaceuticals	1.7887 of 5 stars	$5.44 -6.2%	$20.00 +267.6%	-3.8%	$8.48M	N/A	N/A	5	Positive News
SRNE Sorrento Therapeutics	N/A	$0.00 +28.6%	N/A	-88.0%	$496K	$60.32M	N/A	800	Gap Down
CERO CERo Therapeutics	1.4203 of 5 stars	$0.01 +13.8%	$30.00 +329,570.3%	-99.8%	$411K	N/A	N/A	8	Gap Up
PRPH ProPhase Labs	N/A	$0.03 -7.1%	N/A	-99.4%	$390K	$5.06M	N/A	130	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, SRNE, CERO, PRPH, and NKGN

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Sorrento Therapeutics?

Summary

How does Petros Pharmaceuticals compare to CERo Therapeutics?

Summary

How does Petros Pharmaceuticals compare to ProPhase Labs?

Summary

How does Petros Pharmaceuticals compare to NKGen Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, SRNE, CERO, PRPH, and NKGN

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Do insiders & institutionals have more ownership in PTPI or CNSP?

Does the media favor PTPI or CNSP?

Is PTPI or CNSP more profitable?

Which has preferable earnings & valuation, PTPI or CNSP?

Which has more volatility & risk, PTPI or CNSP?

Do analysts rate PTPI or CNSP?

Summary

How does Petros Pharmaceuticals compare to Sorrento Therapeutics?

Do insiders and institutionals hold more shares of PTPI or SRNE?

Which has more volatility & risk, PTPI or SRNE?

Which has stronger earnings & valuation, PTPI or SRNE?

Does the media favor PTPI or SRNE?

Is PTPI or SRNE more profitable?

Summary

How does Petros Pharmaceuticals compare to CERo Therapeutics?

Which has more volatility & risk, CERO or PTPI?

Which has better earnings & valuation, CERO or PTPI?

Do insiders & institutionals believe in CERO or PTPI?

Does the media prefer CERO or PTPI?

Do analysts recommend CERO or PTPI?

Is CERO or PTPI more profitable?

Summary

How does Petros Pharmaceuticals compare to ProPhase Labs?

Does the media refer more to PRPH or PTPI?

Do analysts prefer PRPH or PTPI?

Is PRPH or PTPI more profitable?

Which has more volatility & risk, PRPH or PTPI?

Which has higher valuation & earnings, PRPH or PTPI?

Do institutionals & insiders have more ownership in PRPH or PTPI?

Summary

How does Petros Pharmaceuticals compare to NKGen Biotech?

Does the media refer more to PTPI or NKGN?

Which has preferable earnings and valuation, PTPI or NKGN?

Is PTPI or NKGN more profitable?

Which has more risk and volatility, PTPI or NKGN?

Do institutionals & insiders believe in PTPI or NKGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools